Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-hodgkin Lymphoma · Acute Lymphoblastic Leukaemia · Chronic Lymphocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

InstituteHBDH, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (ZHEN JING, MM) · jing.zhen@cytocares.com · 86-21-50582090
Contact: Principal Investigator (JUNYUAN QI, MD)

Study leads

JUNYUAN QI, MD
Principal Investigator
Institute of Hematology & Blood Diseases Hospital, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System Neoplasm · Histiocytic Sarcoma · Malignant Histiocytosis

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · Rochester, United States

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Diffuse Large Cell Lymphoma · Non-Hodgkin Lymphoma · Burkitt Lymphoma

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-Cell · Lymphoma, Non-Hodgkin (NHL) · Lymphoma, Large B-Cell, Diffuse (DLBCL)

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Chicago, United States

SynKIR-310 for Relapsed/Refractory B-NHL

B Cell Lymphoma · NHL, Adult · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Atlanta, United States